These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 17713766

  • 21. The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction.
    Müller J, Hüllner M, Strobel K, Huber GF, Burger IA, Haerle SK.
    Laryngoscope; 2015 Aug; 125(8):1861-8. PubMed ID: 25892275
    [Abstract] [Full Text] [Related]

  • 22. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 23. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
    Niccoli-Asabella A, Altini C, Notaristefano A, Merenda N, Altieri ML, Stabile-Ianora AA, Fanelli M, Rubini G.
    Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
    [Abstract] [Full Text] [Related]

  • 24. The use of 18F-FDG PET/CT in colorectal liver metastases--comparison with CT and liver MRI.
    Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, Cunningham D, Cook GJ.
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1323-9. PubMed ID: 18347794
    [Abstract] [Full Text] [Related]

  • 25. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A, Kalinyak JE, McDougall IR.
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [Abstract] [Full Text] [Related]

  • 26. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z, Szefer J, Zuchora Z, Romanowicz G, Pietrzak T.
    Pol Merkur Lekarski; 2004 Sep; 17 Suppl 1():63-6. PubMed ID: 15603351
    [Abstract] [Full Text] [Related]

  • 27. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation.
    Grut H, Revheim ME, Line PD, Dueland S.
    Nucl Med Commun; 2018 Jul; 39(7):621-627. PubMed ID: 29683930
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Performance of 18F-FDG PET/contrast-enhanced CT in the staging of squamous cell carcinoma of the oral cavity and oropharynx.
    Krabbe CA, Balink H, Roodenburg JL, Dol J, de Visscher JG.
    Int J Oral Maxillofac Surg; 2011 Nov; 40(11):1263-70. PubMed ID: 21824748
    [Abstract] [Full Text] [Related]

  • 33. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
    Song HJ, Cheng JY, Hu SL, Zhang GY, Fu Y, Zhang YJ.
    Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Diagnostic value of ¹⁸F-fluorodexyglucose positron emission tomography combined with contrast enhanced computed tomography in colorectal cancer liver metastasis].
    Zhang Z, Lyu Q, Chen F, Liao S, Zhang J, Hu R, Hu P.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):238-42. PubMed ID: 25809326
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Performance of FDG PET/ceCT in the evaluation of patients with lung cancer.
    Nanni C, Rossetti V, Zompatori M, Ambrosini V, Montesi V, Mascherini D, Pettinato C, Marzola MC, Colletti PM, Rubello D, Fanti S.
    Biomed Pharmacother; 2014 Mar; 68(2):219-23. PubMed ID: 24486108
    [Abstract] [Full Text] [Related]

  • 38. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S.
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [Abstract] [Full Text] [Related]

  • 39. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
    Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, Rubini G.
    Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
    [Abstract] [Full Text] [Related]

  • 40. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y, Kitajima K, Fukushima K, Mouri M, Doi H, Oshima T, Niwa H, Kaibe N, Sasako M, Tomita T, Miwa H, Hirota S.
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.